遭股东“清仓式”减持，昭衍新药A股跌停

Core Viewpoint - The major shareholder of Zhaoyan New Drug has announced a significant reduction plan, which has led to a sharp decline in the company's stock prices, indicating potential concerns about the company's financial health and market position [1][2]. Group 1: Shareholder Reduction Plan - The shareholder Gu Xiaolei and his associate Gu Meifang plan to reduce their holdings by up to 30.74 million shares within three months, which represents 4.1026% of the company's total shares [1]. - Following the announcement, Zhaoyan New Drug's A-shares and H-shares experienced a significant drop, with A-shares closing at 29.32 yuan per share, down to a total market value of 21.97 billion yuan [1]. Group 2: Company Background and Business Operations - Zhaoyan New Drug, established in 1995, is a leading provider of drug research and development outsourcing services in China, primarily focusing on non-clinical safety evaluation services [2]. - The company is recognized for its substantial reserves of experimental monkeys, making it a prominent player in the industry, often referred to as "Monkey King" in the secondary market [2]. Group 3: Financial Performance - The company's revenue has been declining due to intensified industry competition and falling market prices for biological assets (experimental monkeys), with revenues recorded at 2.268 billion yuan, 2.376 billion yuan, and 2.018 billion yuan from 2022 to 2024 [2]. - For 2025, the company anticipates revenues between 1.573 billion yuan and 1.738 billion yuan, representing a year-on-year decrease of approximately 13.9% to 22.1%, while net profit is expected to increase significantly by 214% to 371% [3]. - The increase in net profit is attributed to rising market prices for biological assets and natural growth appreciation, despite a decline in profit contributions from laboratory services due to previous intense competition [3].